Abdominal

Abdominal Body Fat Could Hint at CVD Risk, Even When Other Health Factors Are Not Considered

Having a high body roundness index (BRI) over a 6-year period was associated with an increased risk of developing cardiovascular disease (CVD) for adults aged older than 45 years, according to a study published in the Journal of the American Heart Association. BRI is an abdominal obesity-related index that combines waist circumference and height, reflecting the proportion of abdominal and visceral fat. In contrast, body mass index (BMI) only measures weight in relation to height. Previous research has suggested that BRI is a valuable predictor of CVD  risk and may help determine the presenc...

Stroke Rates in People With Sickle Cell Disease Are Increasing Despite Treatment Guidelines

The incidence of stroke continues to increase for adults and children living with sickle cell disease (SCD) despite the Stroke Prevention Trial in Sickle Cell Anaemia (STOP) establishing standards-of-care treatments and tests for those deemed high-ri...

Study presents global estimates of antimicrobial resistance burden

A study published in The Lancet presented the first comprehensive assessment of the global burden of antimicrobial resistance (AMR) from 1990 to 2021, with results forecasted until 2050. “To date, there have been no studies that produce comprehens...


Sixty Seconds Science


Spotify episodes

Apple podcasts

Google podcasts

Partner

Search:
Date
Filters:
Treatment
5:31

Treatment of cervical cancer in 2024 in the highlight of KEYNOTE-A18 study

Presenter: Remi Nout
Oncology
ESMO 2024
Adjuvant P
3:33

Adjuvant Pembrolizumab/Chemotherapy Misses DFS End Point in High-Risk Endometrial Cancer, but Benefits dMMR Subgroup

Presenter: Remi Nout
Oncology
ESMO 2024
Breast can
5:60

Breast cancer, early stage highlights of the ESMO 2024 Congress

Presenter: Ann H. Partridge
Oncology
ESMO 2024
Setting a
5:24

Setting a new benchmark for ALK+ aNSCLC targeted therapy - report from ESMO2024

Presenter: Tony S.K. Mok
Oncology
ESMO 2024
POD1UM-303
1:41

POD1UM-303/InterAACT 2: Potentially Practice-Changing Findings in SCAC - report from ESMO2024

Presenter: Dominik P. Modest
Oncology
ESMO 2024
Neoadjuvan
6:26

Neoadjuvant pembrolizumab or placebo plus chemotherapy followed by adjuvant pembrolizumab or placebo for high-risk early-stage TNBC: Overall survival results from the phase 3 KEYNOTE-522 study

Presenter: Peter Schmid
Oncology
ESMO 2024
PEACE-3 Tr
5:08

PEACE-3 Trial Shows Combination Therapy Improves Survival in Prostate Cancer

Presenter: Silke Gillessen
Oncology
ESMO 2024
Adding Met
4:05

Adding Metformin to ADT for Patients with mHSPC: Overall Survival Results from the Multi-Arm, Multi-Stage Randomized Platform Trial STAMPEDE

Presenter: Silke Gillessen
Oncology
ESMO 2024
New pillar
12:05

New pillars of optimal medical treatment in heart failure

Presenter: Michael Böhm
Cardiology
ESC 2024
Imroving L
6:14

Imroving Lung Health in the 21's century

Presenter: Joan B. Soriano
Respiratory
ERS 2024
Why is idi
10:26

Why is idiopathic pulmonary fibrosis not so idiopathic? - report from ERS2024

Presenter: Michael Kreuter
Respiratory
ERS 2024
Highlihts
18:36

Highlihts of ERS 2024 - The President's perspective

Presenter: Carlos Robalo Cordeiro
Respiratory
ERS 2024
Novel rese
3:23

Novel research data on asthma and chronic obstructive pulmonary disease management: clinical applications

Presenter: Charlotte Suppli Ulrik
Respiratory
ERS 2024
Thoracic o
9:49

Thoracic oncology - Lung cancer diagnostics and treatment challenges

Presenter: Maria Joana Pereira Catarata
Respiratory
ERS 2024
Overcoming
7:11

Overcoming the challenges of increasing urbanisation for respiratory health

Presenter: Ane Johannessen
Respiratory
ERS 2024
Pre-diabet
6:54

Pre-diabetes: a risk factor for cardiovascular disease? - report from ESC2024

Presenter: Antonio Ceriello
Cardiology
ESC 2024
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease: Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology
The import
11:22

The importance of the anterior interface in eye surgery

Presenter: Marie-José Tassignon
Internal Medicine
Haematolog
17:26

Haematology is at the forefront - interview with EHA President

Presenter: Antonio Almeida
Oncology
Overall Su
13:30

Overall Survival Results of KEYNOTE-564

Presenter: Stefan N. Symeonides
Oncology
General as
1:18

General aspects of the ESH2023 Hypertension Guidelines - What are the major changes?

Presenter: Michel Burnier
Cardiology
How shall
1:23

How shall be treat hypertension and look at cardiac risk factors when we consider proper treatment?

Presenter: Konstantinos Tsioufis
Cardiology
How to tre
1:06

How to treat patients optimally with chronic coronary syndromes in 2023?

Presenter: Luis Henrique Gowdak
Overall Su
20:13

Overall Survival Results of KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma

Presenter: David F. McDermott
Oncology
How novel
1:07

How novel AI model may help physicians distinguish and identify prefibrotic primary myelofibrosis from essential thrombocythemia?

Presenter: Andrew Srisuwananukorn
Hematology
The future
1:10

The future of Multiple Myeloma management

Presenter: Xavier Leleu
Hematology
Benefits o
1:01

Benefits of myeloma regimens in the real world fall well short of trials

Presenter: Alissa Visram
Hematology
The prefer
0:57

The preferred treatment of hypertension with RAAS blockade inhibitors

Presenter: Martin Strauss
Cardiology
What clini
1:16

What clinicians should know about the new ESH guideline regarding hypertension in women?

Presenter: Renata Cifkova
Cardiology
How to man
1:00

How to manage isolated systolic hypertension in the young?

Presenter: Paolo Palatini
Cardiology
Blood pres
1:34

Blood pressure monitoring in general and what we can do to encourage people.

Presenter: Neil Poulter
Cardiology
How to man
1:08

How to manage masked and masked uncontrolled hypertension?

Presenter: Paolo Palatini
Cardiology
ESMO 2023
1:13

ESMO 2023 Scientific Chair's welcome and invitation to next year's ESMO Congress

Presenter: Silke Gillessen
Oncology